Abstract：
BACKGROUND: Gut microbiome is a community of microorganisms that lives in the human intestine and exerts various functions on the host, including metabolic, immunoregulatory, and control over cell proliferation. Gut microbiome alterations have been associated with various pathological conditions, such as diabetes mellitus, obesity, and cardiovascular diseases. Gut-prostate axis is explained by the association between gut microbiome quantitative and functional alterations along with increased intestinal epithelial permeability with prostatediseases. However, the pathophysiological mechanisms and clinical importance of this association are not completely clarified yet.
METHODS: We conducted a narrative review of the most relevant articles in the Medline (US National Library of Medicine, Bethesda, MD, USA), Scopus (Elsevier, Amsterdam, The Netherlands) and Web of Science Core Collection (Thomson Reuters, Toronto, ON, Canada) databases. No chronological restrictions were applied, and the most related papers published until December 2023 were included.
RESULTS: Gut microbiota (GM) and its metabolites are capable of modifying host androgen level, as well as prostate cancer (PCa) therapy response. Moreover, patients with inflammatory bowel disease have higher rates of prostatitis-like symptoms and a potential risk of developing PCa.
CONCLUSIONS: There is evidence that interventions on the GM and its metabolites have a high potential to serve as diagnostic and therapeutic tools for prostate diseases, including PCa.
METHODS: We conducted a narrative review of the most relevant articles in the Medline (US National Library of Medicine, Bethesda, MD, USA), Scopus (Elsevier, Amsterdam, The Netherlands) and Web of Science Core Collection (Thomson Reuters, Toronto, ON, Canada) databases. No chronological restrictions were applied, and the most related papers published until December 2023 were included.
RESULTS: Gut microbiota (GM) and its metabolites are capable of modifying host androgen level, as well as prostate cancer (PCa) therapy response. Moreover, patients with inflammatory bowel disease have higher rates of prostatitis-like symptoms and a potential risk of developing PCa.
CONCLUSIONS: There is evidence that interventions on the GM and its metabolites have a high potential to serve as diagnostic and therapeutic tools for prostate diseases, including PCa.
摘要：
背景：肠道微生物组是生活在人体肠道中并在宿主上发挥各种功能的微生物群落，包括新陈代谢，免疫调节,并控制细胞增殖。肠道微生物组改变与各种病理状况有关，比如糖尿病，肥胖，和心血管疾病。肠道-前列腺轴通过肠道微生物组数量和功能改变以及前列腺疾病的肠上皮通透性增加之间的关联来解释。然而,这种关联的病理生理机制和临床重要性尚未完全阐明.
方法：我们对Medline（美国国家医学图书馆，贝塞斯达,MD,美国),Scopus(Elsevier,阿姆斯特丹,荷兰)和WebofScience核心合集(汤森路透，多伦多,ON,加拿大)数据库。没有应用时间顺序限制，和直到2023年12月发表的最相关的论文都包括在内。
结果：肠道菌群（GM）及其代谢产物能够改变宿主雄激素水平，以及前列腺癌（PCa）治疗反应。此外，炎症性肠病患者的前列腺炎样症状发生率较高,并且有发生PCa的潜在风险.
结论：有证据表明，对GM及其代谢物的干预措施具有很高的潜力，可以作为前列腺疾病的诊断和治疗工具，包括PCA。
方法：我们对Medline（美国国家医学图书馆，贝塞斯达,MD,美国),Scopus(Elsevier,阿姆斯特丹,荷兰)和WebofScience核心合集(汤森路透，多伦多,ON,加拿大)数据库。没有应用时间顺序限制，和直到2023年12月发表的最相关的论文都包括在内。
结果：肠道菌群（GM）及其代谢产物能够改变宿主雄激素水平，以及前列腺癌（PCa）治疗反应。此外，炎症性肠病患者的前列腺炎样症状发生率较高,并且有发生PCa的潜在风险.
结论：有证据表明，对GM及其代谢物的干预措施具有很高的潜力，可以作为前列腺疾病的诊断和治疗工具，包括PCA。
